VanEck Associates
ACOR

VanEck Associates’s Acorda Therapeutics ACOR Stock Holding History

VanEck Associates’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-796
Closed -$3.15M – 659
2013
Q2 		$3.15M Buy
+796
New +$3.28M 0.02% 257

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

VanEck Associates's ACOR Position: Q3 2013 in Review

VanEck Associates sold out of Acorda Therapeutics (ACOR) in Q3 2013, closing a stake of 796 shares — an estimated $3.15M sold.

VanEck Associates first reported a position in ACOR in Q2 2013 and held it in 1 quarter. The position peaked at $3.15M in Q2 2013. 153 funds tracked by Wall St. Rank hold ACOR as of Q3 2013.

  • VanEck Associates reported no remaining Acorda Therapeutics position as of Q3 2013 after selling out during the quarter.
  • VanEck Associates sold 796 Acorda Therapeutics shares in Q3 2013, an estimated $3.15M.
  • VanEck Associates first reported a position in Acorda Therapeutics in Q2 2013 and held it in 1 quarter.
  • VanEck Associates's Acorda Therapeutics position peaked at $3.15M in Q2 2013.
  • 153 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2013.

Based on VanEck Associates's 13F filing for Q3 2013, filed 14 Nov 2013.